Status and phase
Conditions
Treatments
About
The primary purpose of this study is to evaluate the change at the 18th week from baseline in daily "off" time measured by participant diary and Parkinson's Disease Questionnaire-39 (PDQ-39) in participants with Parkinson's Disease who are receiving levodopa.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Male or female, age greater than or equal to (>=) 19 years at the time of informed consent
Participants who meet the clinical diagnostic criteria of Movement Disorder Society (MDS) diagnostic criteria 2015 for Parkinson's disease, have motor fluctuations with >=1.5 hours of "off" time throughout the day which is confirmed at the time of Screening, and take levodopa 3 or more times a day
Parkinson's Disease participants who are receiving levodopa without Catechol O-methyltransferase (COMT) inhibitor and/or Monoamine oxidase-B (MAO-B) inhibitor
Be able to maintain an accurate and complete diary with the help of a caregiver as needed, recording "on" time, "on" time with dyskinesia, "off" time, and time asleep
Be able to provide written informed consent
Participants whose cognitive function, at the discretion of an investigator, is at a level appropriate to participate in the clinical trial (that is., with a Global Deterioration Scale [GDS] score of 3 or less or a Clinical Dementia Rating [CDR] of 0.5 or less within 3 months prior to screening)
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
201 participants in 1 patient group
Loading...
Central trial contact
Elena Yoona Lee
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal